doi: 10.1111/dom.12849 32 SimRChongCWLoganadanNKFongAYYNavaravongLHusseinZet al
[150] In November 2025, the United States President Donald Trump announced a deal with NovoNordisk to lower the costs of Ozempic, including monthly prices of about $245 for injectables and $149 for some oral versions for people on Medicare and Medicaid and for those who use his TrumpRx platform
Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]
Approval was granted on the basis that it had been shown to achieve a weight loss of over 25 percent or more in over a third of the participants in clinical trials
20, 2025 from Transportation Security Administration (TSA-a)
This is because GLP-1 agonists are also effective for weight loss, and semaglutide (the active Ozempic ingredient) is licensed under the brand name Wegovy for weight loss in the UK